https://t.co/wMnS1SqyMh

#ICYMI: I was invited to present at the @Oppenheimer Health Conference to discuss @ReunionNeuro's approach to creating innovative tools to combat the global mental health crisis. Check out the presentation for an in-depth look at Reunion's story: https://t.co/rlxZzfioyY $REUN

Check out this recent article by Ruetir, which spotlights how scientific notoriety is growing for the therapeutic potential of psychoactive drugs and my perspective on the elements of preparation and integration sessions in these therapy structures: https://t.co/7fdMUlxrUC $REUN

I could not be more thrilled with Dr. Fred Grossman’s appointment to our Board of Directors. With his veteran leadership in the biotech sector, @ReunionNeuro will continue to advance novel and effective mental health solutions for patients in dire need: https://t.co/ywraJhAXND

.@ReunionNeuro’s Chief Medical Officer, Dr. Robert Alexander, will host a poster presentation at @ASCPorg's 2023 Annual Meeting. Read on for more about the full RE104 dataset from our first-in-human Phase 1 study and an overview of our Phase 2 trial: https://t.co/MGQa1kf88Z $REUN

.@ReunionNeuro's CSO, Dr. Nathan Bryson, presented our mission to develop innovative therapeutic solutions for underserved mental health conditions at @ASENT_Org's 2023 Annual Meeting on the “Early Development Strategy & Patenting of Psychedelics”: https://t.co/ceskODncHe $REUN

I had the pleasure of joining @GlobeMarketNews host @LeylaGulenFOX24 for an exclusive interview to discuss the latest developments for @ReunionNeuro, including our recent CMO appointment, the completion of our Phase 1 clinical trial analysis & more: https://t.co/tKB7OI7TZf $REUN

The revival of next-gen mental health therapeutics is here. Check out my byline in @statnews on the regulatory complexities of alternative medicine & how @ReunionNeuro's #psychedelic molecules could combat the limitations of traditional therapies: https://t.co/3CGX4eBv8O $REUN

Looking forward to @sxsw this week to network with leaders in the #psychedelic space and represent @ReunionNeuro as an innovator in clinical stage biopharmaceuticals. If you’re around, let’s connect and start some conversations: letsconnect@reunionneuro.com $REUN #SXSW #SXSW2023

Join @ReunionNeuro's management team for a virtual corporate presentation at the @Oppenheimer Annual Healthcare Conference on Tuesday, March 14th, at 4 pm ET. Details: https://t.co/KeCxyuNXKs $REUN #biotechnology #Oppenheimer

According to @WSJ, Wall Street is pivoting focus to the multi-million dollar #psychedelic-therapy industry, as it becomes more evident that mental illness can be treated for a fraction of what traditional pharmaceuticals cost. Read on for details: https://t.co/3KjoIIJviG $REUN

.@ReunionNeuro's CMO, Dr. Robert Alexander, shares with @Leafly that short-term psychosis during a #psilocybin experience can yield uniquely beneficial therapeutic effects, despite initial challenges and fears. Head to the full feature for more: https://t.co/gvoWeK22uT $REUN

Some mothers are gravitating towards the potential for #psychedelic therapy to treat #perinatal mental health disorders to avoid the unwanted side effects associated with SSRIs. Head to @washingtonpost for patient testimonials, resources and more: https://t.co/NkEGG7z2cT $REUN

The demand for #mentalhealth services continues to soar in the U.S., catalyzing stronger awareness of the unmet needs of patients and inspiring the advancement of @ReunionNeuro's novel, psychedelic-inspired therapeutic molecules. Full piece via @WSJ: https://t.co/t9lmp4Azfj $REUN

@fieldtriphealth CEO+Co-Founder @RonanDLevy on #ketamine assisted therapy + what investors should look for in the #psychedelic space. $REUN $FTHWF $FTHW.TO https://t.co/Gwl4UouLXv

As companies across the U.S. look to bring #psychedelic therapies to market, I joined @BHBusinessNews to share my perspective on current research and @ReunionNeuro's commitment to developing safe, accessible treatments for mental health conditions: https://t.co/DJWM1NLsdD $REUN

Recently, @ReunionNeuro shared an interim data analysis for our Phase 1 clinical trial with lead asset, RE104, a novel serotonergic psychedelic that could treat #PPD. Key findings from the report were featured in @Benzinga, @psyinvest, @PsychHealthNews and @GreenMarketRpt. $REUN

We’re pleased to announce the appointment of Robert Alexander as @ReunionNeuro’s Chief Medical Officer, a strong addition to our team with extensive experience in the #biotech industry. Read how his role will contribute to the development of RE104: https://t.co/rQfYDP6tFJ $REUN

(2/2) The segment will also delve into my experiences as a #biopharma veteran with over two decades of experience. After initially launching a company to develop epilepsy treatment inspired by my son's diagnosis, I returned to CNS research seeking solutions for #mentalhealth.

(1/2) Today at 4 pm ET, I will be joining host Dustin Robinson of Iter Investments for @psyinvest’s ‘The Investor Hotseat’. Tune in for the livestream to learn about @ReunionNeuro's mission, novel clinical pipeline and milestones: https://t.co/fXC0f2dG9c $REUN